Overview

Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC

Status:
Enrolling by invitation
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of nivolumab for patients with advanced HCC undergoing EBRT
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Center, Korea
Collaborator:
Samsung Medical Center
Treatments:
Nivolumab